Proteostasis gains after hours on successful Phase 1 study of PTI-428

Proteostasis Therapeutics (NASDAQ:PTI) is up 8% after hours on the heels of its Phase 1 clinical trial evaluating PTI-428 in cystic fibrosis patients on background Kalydeco (ivacaftor) therapy.

The company says the study met the primary (safety and tolerability) and secondary endpoints (pharmacokinetics) but it did not perform exploratory analyses on other measures (efficacy) due to the small number of enrollees.

https://seekingalpha.com/news/3419825-proteostasis-8-percent-hours-successful-phase-1-study-ptiminus-428